Study to assess safety & tolerability of AZD2281 in combination with Bevacizumab in Patients with Advanced Solid Tumours
Study identifier:D0810C00022
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (Avastin®) In Patients With Advanced Solid Tumours
Medical condition
Neoplasm Metastasis
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2281, Bevacizumab
Sex
All
Actual Enrollment
18
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jun 2008
Primary Completion Date: 01 Mar 2009
Study Completion Date: 01 Nov 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Dose Escalation Study 50, 100, 200, 400 mg | Drug: AZD2281 Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing Other Name: Olaparib Drug: Bevacizumab IV administration10 mg/kg every 14 days Other Name: Avastin |
Contacts
Investigators
Principal Investigator
James Carmichael
KuDOS Pharmaceuticals Ltd
